

Box Sequence 16
PATENT
Attorney Docket No. 4518US

CERTIFICATE OF MAILING (under 37 C.F.R. § 1.10 if checked)

I hereby certify that this transmittal along with all items checked below is being deposited with the United States Postal Service

- ☒ as first class mail, postage prepaid (37 C.F.R. § 1.8)
☐ "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10

Express mail label mailing number:

on the date inserted below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Lynette Eliason
Typed name of person mailing transmittal

August 24, 2001
Date of Deposit

Lynette Eliason
Signature of person mailing transmittal

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUG 29 20

TECH CENTER 160

Examiner: To be assigned

Group Art Unit No.: 1647

Applicant(s): Meloen et al.

Filing date: September 12, 2000

Serial No.: 09/659,983

For (title):

AN IMPROVED PEPTIDE, IMMUNOGENIC
COMPOSITION AND VACCINE OR MEDICAL
PREPARATION, A METHOD TO IMMUNISE ANIMALS
AGAINST THE HORMONE LHRH, AND
THE LHRH TANDEM REPEAT PEPTIDE
USE AS VACCINE

COMMUNICATION TRANSMITTAL

Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed for filing in connection with the above-identified patent application, and submitted in the order listed, are:

- ☒ Postcard receipt acknowledgment (attached to the front of this transmittal).
☒ Duplicate copy of this transmittal sheet in the event that additional filing fees are required under 37 C.F.R. § 1.16. Any such fee to deposit account no. 20-1469.
☐ Check no. in the amount of \$ for the presentation of extra claims as calculated in the remarks section below.
☐ Preliminary amendment.
☐ Amendment or other communication in response to the non-final office action mailed.
☐ Amendment or other communication under 37 C.F.R. § 1.116 in response to the final office action mailed.
☐ Petition for Extension of Time in duplicate with check no. in the amount of \$.
☐ Verified statement(s) to establish small entity status under 37 C.F.R. § 1.9 and 37 C.F.R. § 1.27 signed by (or on behalf of) the applicant.
☐ Information disclosure statement and information disclosure citation form PTO-1449 with copies of listed documents.
☒ Response to notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence.

Remarks:

- ☐ An amendment has been made involving one or more claims in the application. The calculation to determine whether any additional fee is due is presented below.

	1	2	3	EXTRA
Total claims	-	=	x 18.00 =	
Indep. claims	-	=	x 78.00 =	
First presentation of a multiple dep. claim (+260.00)				
SUBTOTAL				
Reduction for small entity - 50% of subtotal*				
TOTAL ADDITIONAL FEE (subtotal minus any reduction)				

*Verified statement(s) must be attached to support this reduction if small entity status has not been previously established.

1 Claims remaining after amendment.

2 Highest number of claims previously paid for. Not less than 20 for total claims and 3 for independent claims.

3 Difference between claims remaining and highest number previously paid for. If less than zero, enter "0."

- ☒ The commissioner is authorized to charge any additional fees required but not submitted with any document or request requiring fee payment under 37 C.F.R. §§ 1.16 and 1.17 to deposit account no. 20-1469 during the entire pendency of this application.


Respectfully submitted,

Allen C. Turner
Reg. No. 33,041
TRASKBRITT
P.O. Box 2550
Salt Lake City, UT 84110-2550
(801) 532-1922

Date: August 24, 2001

Enclosures: As identified above

DISK TO SENDER
AUG 27 2001
PATENT & TRADEMARK OFFICE
DATE:



Notice to Comply

Application No.

09/659,983

Examiner

Regina M. DeBerry

Applicant(s)

MELOEN ET AL.

Art Unit

1647

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY